Antihypertensive Efficacy and Tolerability of Two Fixed-Dose Combinations of Valsartan and Hydrochlorothiazide Compared with Valsartan Monotherapy in Patients with Stage 2 or 3 Systolic Hypertension: An 8-Week, Randomized, Double-Blind, Parallel-Group Trial

Lacourcière, Yves; Poirier, Luc; Hebert, Daniel N.; Assouline, Linda; Stolt, Pelle; Rehel, Bonita; Khder, Yasser

doi:10.1016/j.clinthera.2005.07.010

Cited by 59 publications

(36 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supporting this, according to Everett et al, the incidence of HTN was more commonly seen in patients below 65 years (85.9-87.7%) in comparison to patients above 65 years (12.3-14.0%) [17]. Lacourciere et al [18] and Ruilope et al levels [19] had also been consistent with the current study showing the mean age to be 60-61 years; however; in a study carried out by Yasmeen et al, 31.7% patients belonged to 51-60 years age group followed by 28.9% in 41-50 years age group with the least (3.5%) being 71-80 years age group [20]. The rationale for an increase in blood pressure with age could probably be due to structural changes in the arteries and especially with large artery stiffness [21].…”

Section: Discussionmentioning

confidence: 84%

Comparison of Efficacy and Adverse Drug Reactions of Monotherapy Versus Combination Therapy of Antihypertensives Among Diabetic Hypertensive Patients in a Tertiary Care Hospital

Bairy

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: To compare the efficacy and adverse drug reactions of monotherapy and combination therapy of antihypertensive drugs in diabetic hypertensive patients. Methods:A prospective observational study of 18 months duration was conducted in the Department of Medicine of a tertiary care hospital in South India. A total of 200 patients were included in the study. Using a standard proforma, the details of patients such as demographic data and antihypertensive medications were collected and analyzed for efficacy and safety.Results: Of 200 patients studied, 50% received monotherapy whereas the remaining 50% received combination therapy. There was male preponderance (54%) in the study population, with the mean age being 60.07±11.32 years. In monotherapy group, most commonly prescribed drug was amlodipine (38%), whereas in combination group, angiotensin receptor blocker (ARB) or calcium channel blocker (CCB) + beta blocker (18%) was commonly prescribed among 2-drug group and ARB+ thiazide+ CCB (25.6%) among 3-drug group. Monotherapy and combination therapy were analyzed to be equally efficacious in reducing systolic blood pressure and diastolic blood pressure. Based on the adverse effect profile, monotherapy comparatively produced more adverse effects than combination group. Amlodipine-induced pedal edema (56.7%) was the most common adverse effect observed, and it was predominantly managed by changing it to be a better tolerable CCB, namely cilnidipine. Conclusion:The combination therapy may be a better treatment option in selected patient population.

show abstract

Section: Discussionmentioning

confidence: 84%

Comparison of Efficacy and Adverse Drug Reactions of Monotherapy Versus Combination Therapy of Antihypertensives Among Diabetic Hypertensive Patients in a Tertiary Care Hospital

Bairy

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…[63][64][65][66][67][68][69][70][71] Additionally, tolerability is retained irrespective of dose. In a recent study, 72 valsartan monotherapy (80 mg once daily) was effective in patients with stage 2 or 3 systolic hypertension. Significant additional reductions in SBP and DBP and an increase in responder rates were achieved with valsartan/HCTZ 160/12.5 and 160/25 mg and no significant effect on tolerability was observed.…”

Section: Optimizing Hypertension Management a Heagertymentioning

confidence: 98%

“…Significant additional reductions in SBP and DBP and an increase in responder rates were achieved with valsartan/HCTZ 160/12.5 and 160/25 mg and no significant effect on tolerability was observed. 72 Valsartan/HCTZ 320/12.5 and 320/25 mg once daily have also proven to be efficacious, well-tolerated treatment options. 73 The comparable efficacy 69 but improved tolerability of ARBs in comparison with other classes of antihypertensive agents 66,69 further supports the use of ARB combinations as first-line treatment for hypertension.…”

Section: Optimizing Hypertension Management a Heagertymentioning

confidence: 99%

Optimizing hypertension management in clinical practice

Heagerty

2006

J Hum Hypertens

View full text Add to dashboard Cite

A clear relationship exists between elevated blood pressure (BP) and various manifestations of cardiovascular disease. Despite the availability of numerous treatment guidelines, hypertension remains inadequately controlled, with only a small proportion of patients achieving target BP levels. Many factors, both patient and physician related, contribute to this poor level of hypertension control. Major determinants include the implementation of inappropriate treatment regimens that do not enable patients to achieve goal and poor patient compliance. For example, it is widely acknowledged that most patients require two or more antihypertensive drugs to achieve BP goal; however, physicians may be reluctant to employ such treatment strategies. The aim of this review is to explore factors that contribute to poor hypertension control rates and how to overcome these, including the rationale for selecting combination therapy, with particular reference to angiotensin II receptor blocker combinations.

show abstract

“…The efficacy and safety of the combination of valsartan with HCTZ or amlodipine have been demonstrated in various studies (29)(30)(31)(32)(33)(34)(35)(36)(37). In addition to achieving a greater antihypertensive effect in combination therapy than in monotherapy, a better side effect profile is also obtained.…”

Section: Combination Therapymentioning

confidence: 99%

Hypertension and valsartan

Kızılırmak¹,

Üresin²

2015

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Hypertension, which is pointed to be the most frequent cause of death in the World and in Turkey and defined by the World Health Organization as global health crisis and the prominent risk factor for cardiovascular diseases, is a problem threatening public health. Renin-angiotensin system (RAS) plays an important role in pathophysiology and in turn treatment of the disease. The drugs suppressing RAS are recommended both for monotherapy and combinations. Together with the blood pressure lowering effects and positive contributions of this group of drugs to the cardiovascular and renal process have been proved by clinical studies. In this review, the recent developments about the hypertension treatment were summarized and the place of valsartan molecule, being an angiotensin receptor blocker in hypertension treatment, was examined in the light of the studies in which the effectiveness, tolerability and safety of valsartan were evaluated. (Anadolu Kardiyol Derg 2014; 14(Suppl 2): S20-S4)

show abstract

Antihypertensive Efficacy and Tolerability of Two Fixed-Dose Combinations of Valsartan and Hydrochlorothiazide Compared with Valsartan Monotherapy in Patients with Stage 2 or 3 Systolic Hypertension: An 8-Week, Randomized, Double-Blind, Parallel-Group Trial

Cited by 59 publications

References 17 publications

Comparison of Efficacy and Adverse Drug Reactions of Monotherapy Versus Combination Therapy of Antihypertensives Among Diabetic Hypertensive Patients in a Tertiary Care Hospital

Comparison of Efficacy and Adverse Drug Reactions of Monotherapy Versus Combination Therapy of Antihypertensives Among Diabetic Hypertensive Patients in a Tertiary Care Hospital

Optimizing hypertension management in clinical practice

Hypertension and valsartan

Contact Info

Product

Resources

About